Literature DB >> 24374150

Suramin inhibits EV71 infection.

Yaxin Wang1, Jie Qing2, Yuna Sun3, Zihe Rao4.   

Abstract

Enterovirus-71 (EV71) is one of the major causative reagents for hand-foot-and-mouth disease. In particular, EV71 causes severe central nervous system infections and leads to numerous dead cases. Although several inactivated whole-virus vaccines have entered in clinical trials, no antiviral agent has been provided for clinical therapy. In the present work, we screened our compound library and identified that suramin, which has been clinically used to treat variable diseases, could inhibit EV71 proliferation with an IC50 value of 40 μM. We further revealed that suramin could block the attachment of EV71 to host cells to regulate the early stage of EV71 infection, as well as affected other steps of EV71 life cycle. Our results are helpful to understand the mechanism for EV71 life cycle and provide a potential for the usage of an approved drug, suramin, as the antiviral against EV71 infection.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral; Enterovirus 71; Suramin

Mesh:

Substances:

Year:  2013        PMID: 24374150     DOI: 10.1016/j.antiviral.2013.12.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  18 in total

1.  Identification of Positively Charged Residues in Enterovirus 71 Capsid Protein VP1 Essential for Production of Infectious Particles.

Authors:  Shilin Yuan; Guiming Li; Ying Wang; Qianqian Gao; Yizhuo Wang; Rui Cui; Ralf Altmeyer; Gang Zou
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

Review 2.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  In Vitro and In Vivo Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN.

Authors:  Tao Meng; Qiang Jia; Sek-Man Wong; Kaw-Bing Chua
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 4.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

5.  Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor.

Authors:  Yaxin Wang; Lin Cao; Yangyang Zhai; Zheng Yin; Yuna Sun; Luqing Shang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

6.  Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C.

Authors:  Yaxin Wang; Ben Yang; Yangyang Zhai; Zheng Yin; Yuna Sun; Zihe Rao
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

7.  3,4-Dicaffeoylquinic Acid from the Medicinal Plant Ilex kaushue Disrupts the Interaction Between the Five-Fold Axis of Enterovirus A-71 and the Heparan Sulfate Receptor.

Authors:  Chung-Fan Hsieh; Yu-Li Chen; Guan-Hua Lin; Yoke Fun Chan; Pei-Wen Hsieh; Jim-Tong Horng
Journal:  J Virol       Date:  2022-03-23       Impact factor: 6.549

8.  A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus.

Authors:  Yu Guo; Yaxin Wang; Lin Cao; Peng Wang; Jie Qing; Qizhen Zheng; Luqing Shang; Zheng Yin; Yuna Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

9.  In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71.

Authors:  Yizhuo Wang; Guiming Li; Shilin Yuan; Qianqian Gao; Ke Lan; Ralf Altmeyer; Gang Zou
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.938

10.  The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate.

Authors:  Yorihiro Nishimura; Noel P McLaughlin; Jieyan Pan; Sara Goldstein; Susan Hafenstein; Hiroyuki Shimizu; Jeffrey D Winkler; Jeffrey M Bergelson
Journal:  PLoS Pathog       Date:  2015-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.